Latest Breaking News On - Gensight biologics stock - Page 1 : comparemela.com

Laurence Rodriguez, Appointed CEO of GenSight Biologics in December 2023, Joins the Company s Board of Directors

16.01.2024 - Regulatory News: The Board of Directors of GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the Company ), a biopharma company focused on developing and commercializing innovative gene therapies for retinal .

Laurence rodriguezGensight biologicsSanofi genzymeBernard gillyChief executive officerRare diseasesRare blood disordersAlain sahelSight biologicMitochondrial targeting sequenceLeber hereditary optic neuropathyGensight biologicGensight biologics stock

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

15.11.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system .

France generalGensight biologicsEuropean medicines agencySofinnova partnersSight biologicsBridge financingSight biologicMitochondrial targeting sequenceLeber hereditary optic neuropathyGensight biologicInstitut de la visionAdeno associated virusMedicines agencyProcess performance qualificationGood manufacturing practiceMarketing authorisation application

GenSight Biologics Announces its 2023 Financial Calendar

GenSight Biologics Announces its 2023 Financial Calendar
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Gensight biologicsYear financial updateCash positionHalf financial updateSight biologicMitochondrial targeting sequenceLeber hereditary optic neuropathyGensight biologicGensight biologics stock

GenSight Biologics to Present at Upcoming Investor Conferences

04.01.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system .

France generalGensight biologicsThomas gidoinSecurities biomed forumInvest securities biomedChief financial officerDegroof petercam healthcareSight biologicMitochondrial targeting sequenceLeber hereditary optic neuropathyGensight biologicGensight biologics stock